Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.
Stock data | 2023 | Change |
---|---|---|
Price | $0.30202856991131644 | N/A |
Market Cap | $98.32M | N/A |
Shares Outstanding | 325.53M | 8.68% |
Employees | 0 | N/A |
Shareholder Equity | 5.96M | -58.65% |
Valuation | 2023 | Change |
---|---|---|
P/E Ratio | -7.12 | N/A |
P/B Ratio | 16.49 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | -1.5365 | N/A |
Earnings | 2023 | Change |
---|---|---|
Earnings | -$9.16M | N/A |
EPS | -0.0424 | N/A |
Earnings Yield | -0.1404 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $11.79M | N/A |
Cash on Hand | $5.30M | N/A |
Debt to Equity | $1.31 | 1275.17% |
Current Ratio | $1.51 | -81.47% |